| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afd115dec46c157d3739020ebd4d866b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_864d2e26a096e56f38ce5b14f47c15a8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-805 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-735
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 |
| filingDate |
1993-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c0a691202a91cda5147cc21ab925086
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93c27e3ec915e5382064d0093c5dd919
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa54089b5bd6819a5c73dd71332164d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4055b1827b2e37df743dce3c97418987 |
| publicationDate |
1994-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2141685-A1 |
| titleOfInvention |
Antiallergic composition |
| abstract |
The invention relates to an antiallergic composition comprising, as an active ingredient, a peptide which is capable of binding to human IgE, more specifically a high affinity immunoglobulin E receptor .alpha.-chain or a soluble fragment, which is capable of binding to human IgE, of a high affinity immunoglobulin E receptor .alpha.-chain, (1) an animal cell transfected with a plasmid having inserted therein a DNA coding for sFc.epsilon.R.alpha. linked to a promoter capable of controlling the expression of the DNA in animal cells at upstream site thereof and a DNA coding for DHFR linked to a UK promoter at upstream site thereof, (2) an animal cell cotransfected with a plasmid carrying a DNA coding for sFc.epsilon.RI.alpha. linked to a promoter capable of controlling the expression of the DNA in animal cells at upstream site thereof and a plasmid carrying a DNA coding for DHFR linked to a UK promoter at upstream site thereof, and (3) a process for producing sFc.epsilon.RI.alpha. in a large quantity which comprises cultivating the animal cells of the above (1) or (2). The present invention provides a composition clinically useful for blocking allergic responses at their root. |
| priorityDate |
1992-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |